BASF India Limited
Financial trend (75/100) does the heavy lifting; valuation (5/100) is the drag.
ExpensiveOvervaluedStocksWizard rates BASF India Limited a Sell, scoring 40/100 on our blended model. At ₹3,633.8 it trades above our blended DCF and relative-multiples fair value of ₹1,934.81, about 47% downside to that estimate — we read it as overvalued by 47%. On 38.2x trailing earnings it sits pricier than the Basic Materials median of about 22.2x. The price is about 27% below its 52-week high of ₹4,960.62 and 16% above the low of ₹3,142.26. Financial health scores 95/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. The average analyst target of ₹4,120 implies about 13% upside across 1 analysts. It clears 5 of 13 investability checks, with durability 51, valuation 10 and momentum 43 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,547.85.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-26.75% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell40Piotroski F-score 2/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.0%
- Pass: Low debt (D/E < 0.5): 0.03x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 5%
- Pass: Earnings growing: 155%
- Fail: Net margin ≥ 10%: 2.8%
- Pass: Current ratio > 1.5: 1.69
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.81
- Fail: Piotroski ≥ 7: 2/9
Quarterly results
Annual financials
Shareholding
- Promoter73.8%
- Institutions9.7%
- Public & other16.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 4.81.
Opportunities
- Earnings growing (155% YoY).
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
- Weak Piotroski score (2/9).
Threats
- Rich valuation versus sector peers.
- Trades ~47% above our estimated fair value.
About BASF India Limited
BASF India Limited manufactures and supplies chemicals, materials, and agricultural products for domestic and international markets. Its agricultural solutions include crop protection products such as insecticides, herbicides, fungicides, and plant growth regulators, along with seed treatments. The materials segment produces performance materials including polyurethane, engineering and specialty plastics, and monomers.
BASF India Limited — frequently asked questions
Is BASF India Limited a buy, hold or sell?
StocksWizard currently rates BASF India Limited (BASF) a Sell, based on a blended score of 40/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is BASF India Limited's fair value?
Our blended DCF and relative-valuation model estimates BASF India Limited's fair value at about ₹1,934.81, versus a current price of ₹3,633.8 — roughly 47% downside. On that basis the stock looks overvalued by 47%.
Is BASF India Limited financially healthy?
BASF India Limited scores 95/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.
How has BASF India Limited's share price performed?
BASF India Limited is up 1% over three months, and last traded at ₹3,633.8. Past performance doesn't predict future returns.
More in Basic Materials
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.